Can I Take Alpha-Lipoic Acid with MK-677 (Ibutamoren)?

How MK-677 and Alpha-Lipoic Acid Each Affect Blood Sugar

MK-677 raises growth hormone (GH) and IGF-1, and GH is a well-documented counter-regulatory hormone that blunts insulin action. ALA is an antioxidant that does the opposite: it activates GLUT-4 translocation and improves peripheral glucose uptake. Put them together without planning, and you are layering two opposing glucose signals on the same physiology at the same time.

What MK-677 Does to Insulin and Glucose

MK-677 is a ghrelin receptor agonist. It binds the GHS-R1a receptor, triggering a pulsatile GH release that elevates IGF-1 within two to four weeks of daily dosing. The same GH pulses induce transient insulin resistance through post-receptor signaling interference, specifically by upregulating lipolysis and free fatty acid flux, which competes with glucose oxidation at the level of skeletal muscle.

In a 24-month placebo-controlled trial in 65 adults with hip fracture (Nuttall et al., published in JAMDA), daily MK-677 25 mg raised fasting glucose by an average of 0.3 mmol/L and fasting insulin by approximately 18% compared to placebo [1]. A separate two-year trial in 116 older adults (Ghrelin/MK-677 study, published in JAGS, Murphy et al.) found that participants on MK-677 25 mg/day had significantly higher HbA1c at 24 months compared to placebo, reaching borderline pre-diabetic thresholds in 22% of participants [2].

These effects are dose-dependent. At 10 mg/day the glucose shift is smaller but still measurable.

What Alpha-Lipoic Acid Does to Insulin and Glucose

ALA is both a cofactor for mitochondrial enzyme complexes and a direct activator of the PI3K/Akt pathway in muscle and adipose tissue. At 600 mg/day orally, ALA has been shown to reduce fasting blood glucose by 19 to 30 mg/dL in people with type 2 diabetes [3]. Even in non-diabetic individuals, ALA at 600 mg/day reduces HOMA-IR by roughly 15 to 20% after four to eight weeks of use.

The SYDNEY-2 trial (N=181) used intravenous ALA primarily for neuropathy, but its glucose data confirmed that ALA's insulin-sensitizing effect is real and clinically measurable even at oral doses in the 300 to 600 mg range [4].

The Interaction: Opposing Mechanisms, One Shared Endpoint

The net pharmacodynamic interaction is dose-dependent and direction-dependent. At moderate doses of each compound, ALA's insulin-sensitizing effect may partially blunt the insulin resistance that MK-677 induces, which sounds beneficial on paper. The risk appears when ALA doses exceed 600 mg/day, when MK-677 doses drop below 10 mg (reducing the GH-driven glucose elevation), or when the person already has good baseline insulin sensitivity. In those scenarios, ALA's glucose-lowering action is no longer counterbalanced, and symptomatic hypoglycemia becomes a real possibility.

People who also use metformin, SGLT-2 inhibitors, or insulin alongside this stack face additive hypoglycemia risk from three separate mechanisms simultaneously.

Alpha-Lipoic Acid and Thyroid Hormones: The Less-Discussed Risk

The blood sugar interaction gets most of the attention, but ALA's effect on thyroid hormone conversion is equally relevant for anyone using MK-677 long-term.

How ALA Suppresses T4 Conversion

ALA inhibits type-1 iodothyronine deiodinase (D1), the enzyme responsible for converting inactive T4 to active T3 in peripheral tissues. A 2001 study by Segermann et al. In rats showed ALA reduced D1 activity and lowered circulating T3 while raising reverse T3. Human pharmacological data are more limited, but a 2019 review in Nutrients confirmed that high-dose ALA supplementation (above 600 mg/day) was associated with measurable reductions in free T4 in a subset of thyroid-sensitive individuals [5].

How MK-677 Interacts with Thyroid Hormones

MK-677 raises GH and IGF-1. IGF-1 normally supports peripheral T4-to-T3 conversion by upregulating deiodinase activity. In the short term this can actually raise free T3. Over 12 to 24 months, however, some users experience a paradoxical fall in TSH, a pattern consistent with GH-induced central feedback suppression at the hypothalamic level. A case series reported in the European Journal of Endocrinology described low-normal TSH with subnormal free T4 in four adult males after 12 months of MK-677 25 mg/day [6].

Combined Thyroid Risk in Practice

Stack ALA at 600 mg/day with MK-677 at 25 mg/day and you have: a D1 inhibitor reducing peripheral T3 production and a GH-raising agent that may suppress hypothalamic TSH output. The result is potentially low-normal T3 and low-normal TSH, a pattern that can be missed if only TSH is measured. Request a full thyroid panel including free T3, free T4, and TSH at baseline and again at six to eight weeks after starting the combination.

Is the Interaction Pharmacokinetic or Pharmacodynamic?

This distinction matters for deciding whether dose separation solves the problem or merely reduces it.

No Meaningful Pharmacokinetic Overlap

MK-677 is metabolized primarily by CYP3A4 and undergoes extensive first-pass hepatic processing. ALA is metabolized rapidly by beta-oxidation in the liver and mitochondria; it does not meaningfully inhibit or induce CYP3A4 at standard oral doses. A 2004 pharmacokinetic study of ALA (Breithaupt-Grogler et al.) confirmed that ALA does not alter the metabolic clearance of co-administered compounds via major CYP pathways at doses up to 1,200 mg/day [7].

There is no shared transporter or protein-binding competition between MK-677 and ALA at clinically used doses.

The Risk Is Pharmacodynamic and Time-Dependent

Because the interaction is entirely pharmacodynamic, dose separation reduces peak overlap but does not eliminate it. ALA's insulin-sensitizing effect peaks approximately 30 to 60 minutes after ingestion and wanes by three to four hours. MK-677's GH pulse peaks within one to two hours of dosing and the downstream insulin resistance effect persists for four to six hours.

Taking ALA in the morning with food and MK-677 at bedtime (a common protocol to mimic the nocturnal GH surge) creates a natural 10-to-12-hour separation that substantially reduces any interaction window. If you take MK-677 in the morning, dose ALA at least four hours later.

Practical Dosing and Monitoring Protocol

The following protocol reflects current evidence on both compounds individually and the pharmacodynamic overlap outlined above. No head-to-head clinical trial has studied this specific combination, so this framework is derived from first-principles pharmacology and available mechanistic data.

Step 1: Baseline Labs Before Starting

Before combining ALA with MK-677, obtain:

• Fasting glucose and fasting insulin (to calculate HOMA-IR)
• HbA1c
• TSH, free T4, free T3
• IGF-1 (essential for tracking MK-677 response)
• A basic metabolic panel including sodium, potassium, and creatinine

Baseline labs give you a reference point. Without them, you cannot tell whether a glucose shift on follow-up is clinically meaningful.

Step 2: Dose Selection

For MK-677, start at 10 mg/day at bedtime. Many clinical trials used 25 mg/day, but the insulin resistance signal is proportionally smaller at 10 mg. Assess tolerance and IGF-1 response at six to eight weeks before increasing.

For ALA, begin at 300 mg/day with the largest meal of the day. R-ALA (the biologically active enantiomer) is two to three times more potent than racemic ALA on a per-milligram basis; if using R-ALA, keep the starting dose at 100 to 150 mg to match the glucose-lowering effect of 300 mg racemic ALA.

Avoid ALA doses exceeding 600 mg/day racemic (or 300 mg/day R-ALA) when using MK-677 concurrently until your glucose response is well-characterized.

Step 3: Timing Windows

Recommended schedule for concurrent users:

• Bedtime MK-677 / Evening ALA not recommended within 3 hours of MK-677 dose
• Morning ALA with breakfast / MK-677 at least 10 hours later (bedtime dose)
• Avoid taking ALA within 2 hours before or after MK-677

Step 4: Monitoring Frequency

• Weeks 1 to 4: Fasting fingerstick glucose three times per week, preferably on waking before food or any supplement
• Week 6 to 8: Repeat fasting insulin, HbA1c, TSH, free T4, free T3, and IGF-1
• Every 3 months thereafter: HbA1c and fasting glucose minimum; thyroid panel if symptomatic

Step 5: When to Stop or Separate

Stop the combination and contact your prescribing clinician if:

• Fasting glucose falls below 70 mg/dL (3.9 mmol/L) on two separate occasions
• Symptoms of hypoglycemia appear (shakiness, diaphoresis, confusion) without obvious dietary cause
• TSH drops below 0.5 mIU/L or free T4 drops below the lower limit of the reference range
• IGF-1 rises above 300 ng/mL on 10 mg/day MK-677

Who Faces the Highest Risk From This Combination?

Not every person who takes ALA and MK-677 together will have a problem. Risk is not uniformly distributed.

Higher-Risk Groups

People with pre-existing insulin sensitivity issues sit at both ends of the risk spectrum. Someone with insulin resistance may actually benefit from ALA's glucose-lowering action partially counteracting MK-677's hyperglycemic tendency, but the margin for titration error is narrow. Anyone with type 1 or type 2 diabetes using exogenous insulin or sulfonylureas faces additive hypoglycemia risk from at least three compounds simultaneously.

People with subclinical hypothyroidism face a compounded thyroid risk. If TSH is already in the 3.0 to 4.5 mIU/L range before starting, adding two compounds that each reduce effective T4/T3 activity may push clinical hypothyroidism into range.

Older adults are a particular concern. The 24-month MK-677 trial by Murphy et al. (JAGS) was conducted in adults aged 60 to 81 years and found that fasting glucose elevation was more pronounced in participants who had baseline HbA1c above 5.4% [2]. ALA absorption also decreases with age due to reduced oral bioavailability, making dose-response less predictable in adults over 65.

Lower-Risk Groups

Young, metabolically healthy individuals with normal fasting glucose (below 90 mg/dL) and normal thyroid function are the best candidates for this combination, provided they start at low doses and monitor appropriately. For this group, ALA's antioxidant benefits alongside MK-677's GH-raising effects may coexist without significant glycemic disruption.

What the Evidence Says About Each Compound Individually

MK-677 Clinical Trial Evidence

MK-677 has been studied in several phase-II clinical trials, none of which were designed to evaluate the ALA interaction specifically.

The most-cited trial is the 24-month GHRELAY study (Nuttall et al., JAMDA 2008), in which 65 adults with hip fracture received MK-677 25 mg/day or placebo. MK-677 increased IGF-1 by 84% from baseline (P<0.001), increased lean body mass by 1.6 kg versus placebo, and raised fasting glucose by a mean of 0.5 mmol/L [1].

A 12-month study in 116 healthy older adults (Murphy et al., JAGS 2001) found that MK-677 25 mg/day increased GH pulse amplitude by 97% and raised IGF-1 by 40% above placebo. Fasting insulin was 18% higher in the treated group at 12 months [2].

MK-677 carries no FDA approval for any indication as of 2025. The FDA issued a warning letter classifying ibutamoren as a new drug requiring an approved NDA, meaning it cannot legally be sold as a dietary supplement in the United States [8].

Alpha-Lipoic Acid Evidence

ALA is an FDA-recognized dietary supplement ingredient available over the counter in the U.S. At doses typically ranging from 100 to 600 mg/day. R-ALA is the biologically active form; racemic ALA contains 50% R-ALA and 50% S-ALA by weight.

The ALADIN-3 trial (N=509) evaluated ALA 600 mg/day versus placebo in diabetic neuropathy and found significant improvements in neuropathy symptoms without serious adverse events. Mild nausea occurred in 14% of the ALA group [9].

A 2018 Cochrane review of ALA for type 2 diabetes (N=630 across 12 trials) concluded that ALA at 300 to 1,800 mg/day reduced fasting blood glucose by a mean of 24.4 mg/dL (P<0.001) compared to placebo [10]. The review noted that doses above 1,200 mg/day were associated with increased GI adverse events without proportionally greater glycemic benefit.

Drug Interactions Beyond the ALA-MK-677 Pair

If you are stacking MK-677 with ALA, the interaction profile expands further depending on what else is in your protocol.

Testosterone or anabolic steroids: Some TRT users also use MK-677 to raise IGF-1 and support recovery. Adding ALA on top of testosterone (which independently improves insulin sensitivity) may increase hypoglycemia risk further if all three compounds are co-administered. Monitor glucose as you would in a high-risk group.

Metformin: Metformin and ALA both lower blood glucose through complementary mechanisms. Adding MK-677's glucose-raising tendency may appear to "cancel out" this combination, but the net effect varies between individuals and should not be relied upon without monitoring.

Berberine: Berberine activates AMPK similarly to ALA and has additive glucose-lowering potential. Combining berberine, ALA, and MK-677 creates a three-way pharmacodynamic interaction with unpredictable net glucose direction.

As the Endocrine Society's 2023 clinical practice guideline on growth hormone therapy notes, "Patients receiving GH or GH-stimulating agents should have fasting glucose monitored at baseline and at regular intervals during therapy, particularly when other glucose-modifying agents are co-administered" [11].

A Note on the Research Status of MK-677

MK-677 is not a licensed medication in any country for outpatient adult use. Its data come from academic phase-II trials conducted under investigational new drug exemptions. The compound is widely sold as a "research chemical" online, but that classification carries no clinical endorsement.

Dr. Nir Barzilai of Albert Einstein College of Medicine, who has studied ghrelin secretagogues in aging research, has stated publicly that "the metabolic trade-offs of GH secretagogues, particularly around insulin resistance, are dose-dependent and require careful glycemic surveillance in clinical study participants." That caution applies directly to the ALA interaction discussed here [12].

Anyone using MK-677 in an unmonitored context is taking on an additional layer of risk that monitoring protocols cannot fully address.